ArticleVirology journal2025
Detection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a Rapid and Sensitive AlphaLISA-Based Assay for Lassa Virus Glycoprotein Detection.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersons with HIV are prone to other infections. Lassa virus (LASV)coinfection with HIV is a public health concern. Viral hemorrhagic fever caused by LASV has been endemic in parts of West Africa. Clinical diagnosis has been a major challenge for effective management and control because the majority of patients are asymptomatic. As such, rapid diagnosis is desirable for prompt therapeutic intervention and the implementation of control measures. The high prevalence of LASV recorded in Nigeria, a neighboring country, places Cameroon at risk. However, the detection of LASV infection among HIV patients, which we investigated in this study, has not been carried out in Cameroon.
methodsPlasma samples were obtained between December 2021 and April 2022 from 330 HIV-positive patients who provided consent. They were tested for LASV IgG and/or IgM antibodies specific for LASV nucleoprotein and/or prefusion envelope glycoproteins via the ReLASV
resultsAnalysis of these samples revealed that IgG and both IgG and IgM antibodies were detected in 2.4% (8/330) and 1.8% (6/330) of the samples, respectively. Our data revealed that both IgG and IgM antibodies do not depend (p > 0.05) on age, sex, or duration of antiretroviral therapy (ART), although the prevalence was high in individuals < 25 years of age, males, and those who had taken ART for < 5 years. The mean ODs of both IgG (0.6 0vs 0.03) and IgM (0.88 vs. 0.04) were significantly greater (p < 0.05) between LAVS-positive and LAVS-negative patients.
conclusionsThe finding of this study shows co-infection of HIV and Lassa Virus. The presence of LASV-specific antibodies suggests exposure to LASV. These findings have direct implications for understanding the transmission risk, mitigation, and prevention and control of LASVs in Cameroon. Our results indicate the urgent need to extend LASV surveillance if there is recurrent LASV infection in any country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.